Assets

Bispecific Antibody Assets

Bispecific antibodies (BsAbs) are engineered antibodies capable of simultaneously binding to two different antigens or epitopes. Compared to monoclonal antibodies and combination therapies, BsAbs demonstrate higher efficacy, lower resistance, and a broader range of applicability due to new functional capabilities. They are expected to have lower toxicity than combined monoclonal antibody treatments. As a result, BsAbs are regarded as a new generation of antibody therapies.
  • 10+
    Fully-human BsAbs
  • 10+
    TCR mimic Assets
Request Data Package Schedule a Meeting
related resource

on this page

  • Why choose Biocytogen's BsAb portfolio?
  • Our BsAb&Tri-Ab assets currently open for partnership
  • Selected assets overview

Webinars

View All

    Posters

    View All
      Why choose Biocytogen's BsAb portfolio?
      • Produced by Biocytogen's proprietary RenLite mice platform and generated by size unlimited chromosome engineering technology (SUPCE), it features a diversified heavy chain sequence repertoire similar to that of humans.
      • RenLite-derived bsAbs have high binding affinity and high specificity.
      • BsAbs span multiple areas including oncology, inflammation and autoimmunity.
      • At Biocytogen, we adhere to the highest standards of quality and scientific rigor. Fully human bispecific antibodies have demonstrated excellent developability and efficacy through in vivo testing.
      • We provide multiple collaboration models, including licensing, transfer, and co-development of bsAbs, and have established partnerships with numerous industry leaders. We warmly invite you to collaborate with us for the benefit of patients worldwide!
      Our BsAb&Tri-Ab assets currently open for partnership
      Format Therapeutic Area Target(s) Immunization
      • Development
      • Hits
        selection         Leads
        selection         Candidate
        selection
      		Preclinical IND Phase I Status
      BsAb Oncology PD-1 x CD40
      		Partnered
      BsAb Oncology OX40 x CTLA4
      BsAb Oncology 4-1BB x CD40
      BpAb Inflammation and Autoimmunity OX40 x OX40
      		Exclusive MTA evaluation ongoing
      BsAb Oncology PD-L1 x 4-1BB
      BsAb Oncology CTLA4 x TNFR2
      BsAb Oncology TIGIT x IL21
      BsAb Oncology OX40 x 4-1BB
      BsAb Oncology CD70 x EGFR
      BsAb Oncology PD-1 x VEGFA
      BsAb Oncology GDF15 x VEGFA
      BsAb Inflammation and Autoimmunity FCGRT x C2
      BsAb Metabolism IGHE x ASGR1
      Tri-Ab Oncology DLL3 x CD3E x 4-1BB
      Tri-Ab Oncology PD-L1 x GDF15 x VEGFA
      Tri-Ab Oncology PD-L1 x VEGFA x ALB
      Tri-Ab Oncology CDH17 x CD3E x 4-1BB
      Tri-Ab Oncology CD3 x DLL3 x ALB
      Tri-Ab Oncology EGFR x PD-L1 x VEGFA
      Tri-Ab Oncology PD-L1 x EGFR x MET
      Tri-Ab Oncology GDF15 x VEGFA x PD-1
      Tri-Ab Oncology, Autoimmunity PD-1 x LAG-3 x TNF
      Selected assets overview

      In addition, Biocytogen also has TCR-like antibody (TCRmimic) assets used for assembling bispecific antibodies with CD3. Contact us today to explore evaluation/licensing/co-development opportunities!

      4-1BB x CD40 fully human bsAb (BCG021) for oncology
      Highlights of our assets:
      • Conditional 4-1BB and CD40 agonistic activity dependent on crosslinking of both targets
      • Potent in vivo anti-tumor activity and significantly improved tumor growth inhibition when combined with anti-PD-1 mAb
      • Desirable physicochemical properties
      • Good in vivo safety in mice
      • Antibody-like PK profile in mice
      • Patent application has been submitted